Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of MGL-3196 in Hepatic Impairment and NASH
NCT04643795Phase 1Completed
- Sponsor
- Madrigal Pharmaceuticals
- Start
- Oct 2018
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of resmetirom in Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by Madrigal Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration at 16 days, Time to Maximum Plasma Concentration at 16 days and 3 more. Started Oct 2018; status: completed.
02
Drugs
resmetirom
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04643795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04643795.